公开(公告)号：US20240189322A1

公开(公告)日：2024-06-13

申请号：US18516091

申请日：2023-11-21

Applicant: Genzyme Corporation

Inventor： John L. KANE, JR. ,  Gloria MATTHEWS ,  Markus METZ ,  Michael KOTHE ,  Jinyu LIU ,  Andrew SCHOLTE

IPC: A61K31/551 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D519/00 ,  C07F9/50 ,  C07F9/6506 ,  C07F9/6558 ,  C07F9/6561

CPC classification number: A61K31/551 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D519/00 ,  C07F9/5022 ,  C07F9/6506 ,  C07F9/65583 ,  C07F9/6561

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

公开(公告)号：US20170224704A1

公开(公告)日：2017-08-10

申请号：US15436195

申请日：2017-02-17

Applicant: Genzyme Corporation

Inventor： John L. KANE, JR. ,  Gloria MATTHEWS ,  Markus METZ ,  Michael KOTHE ,  Jinyu LIU ,  Andrew SCHOLTE

IPC: A61K31/551 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/4725 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/496 ,  A61K31/437 ,  A61K31/4184 ,  A61K31/501

CPC classification number: A61K31/551 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D519/00 ,  C07F9/5022 ,  C07F9/6506 ,  C07F9/65583 ,  C07F9/6561

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

公开(公告)号：US20150158847A1

公开(公告)日：2015-06-11

申请号：US14564773

申请日：2014-12-09

Applicant: Genzyme Corporation

Inventor： John L. KANE, JR. ,  Gloria MATTHEWS ,  Markus METZ ,  Michael KOTHE ,  Jinyu LIU ,  Andrew SCHOLTE

IPC: C07D403/04

CPC classification number: A61K31/551 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D519/00 ,  C07F9/5022 ,  C07F9/6506 ,  C07F9/65583 ,  C07F9/6561

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).